中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2012年
10期
1351-1353
,共3页
宋岩%刘秀萍%白伟良%季文樾
宋巖%劉秀萍%白偉良%季文樾
송암%류수평%백위량%계문월
喉肿瘤/药物疗法%喉肿瘤/中药疗法%顺铂/药理学%喉肿瘤/病理学%黄芪△/药理学
喉腫瘤/藥物療法%喉腫瘤/中藥療法%順鉑/藥理學%喉腫瘤/病理學%黃芪△/藥理學
후종류/약물요법%후종류/중약요법%순박/약이학%후종류/병이학%황기△/약이학
Laryngeal neoplasms/drug therapy%Laryngeal neoplasms/ZHONG YAO LIAO FA%Cisplatin/pharmacology%Laryngeal neoplasms/pathology%ASTRAGALUS MEMBRANACEUS △/pharmacology
目的 研究黄芪与顺铂联合对体外培养的人喉癌Hep-2细胞的抑制作用.方法 用MTT法检测黄芪、顺铂单独或联合作用对人喉癌Hep-2细胞的抑制率;用流式细胞技术及Western-blotting法检测黄芪、顺铂单独或联合作用对人喉癌Hep-2细胞凋亡的影响.结果 作用24h后黄芪组、顺铂组、黄芪联合顺铂组对Hep-2细胞的抑制率分别为(53.83±17.12)％、(69.12±27.12)％、(84.55±27.84)％,与对照组(0％)比较差异有统计学意义(t=16.87,16.67,40.90,P＜0.01).黄芪组、顺铂组、黄芪联合顺铂组Hep-2细胞的凋亡率[(38.2±13.6)％、(67.2±17.8)％、(86.4±25.1)％]与对照组[(17.1±1.3)％]比较差异有统计学意义(t =8.11,12.77,24.92,P＜0.05),且联合用药组的效果较任一单独用药组更为明显(t=11.33,9.37,P＜0.01).结论 黄芪通过促进细胞凋亡有效提高顺铂对Hep-2细胞抑制作用的敏感性,通过调节Bcl-2/Bax蛋白表达,能提高顺铂对喉癌的治疗效果.
目的 研究黃芪與順鉑聯閤對體外培養的人喉癌Hep-2細胞的抑製作用.方法 用MTT法檢測黃芪、順鉑單獨或聯閤作用對人喉癌Hep-2細胞的抑製率;用流式細胞技術及Western-blotting法檢測黃芪、順鉑單獨或聯閤作用對人喉癌Hep-2細胞凋亡的影響.結果 作用24h後黃芪組、順鉑組、黃芪聯閤順鉑組對Hep-2細胞的抑製率分彆為(53.83±17.12)％、(69.12±27.12)％、(84.55±27.84)％,與對照組(0％)比較差異有統計學意義(t=16.87,16.67,40.90,P＜0.01).黃芪組、順鉑組、黃芪聯閤順鉑組Hep-2細胞的凋亡率[(38.2±13.6)％、(67.2±17.8)％、(86.4±25.1)％]與對照組[(17.1±1.3)％]比較差異有統計學意義(t =8.11,12.77,24.92,P＜0.05),且聯閤用藥組的效果較任一單獨用藥組更為明顯(t=11.33,9.37,P＜0.01).結論 黃芪通過促進細胞凋亡有效提高順鉑對Hep-2細胞抑製作用的敏感性,通過調節Bcl-2/Bax蛋白錶達,能提高順鉑對喉癌的治療效果.
목적 연구황기여순박연합대체외배양적인후암Hep-2세포적억제작용.방법 용MTT법검측황기、순박단독혹연합작용대인후암Hep-2세포적억제솔;용류식세포기술급Western-blotting법검측황기、순박단독혹연합작용대인후암Hep-2세포조망적영향.결과 작용24h후황기조、순박조、황기연합순박조대Hep-2세포적억제솔분별위(53.83±17.12)％、(69.12±27.12)％、(84.55±27.84)％,여대조조(0％)비교차이유통계학의의(t=16.87,16.67,40.90,P＜0.01).황기조、순박조、황기연합순박조Hep-2세포적조망솔[(38.2±13.6)％、(67.2±17.8)％、(86.4±25.1)％]여대조조[(17.1±1.3)％]비교차이유통계학의의(t =8.11,12.77,24.92,P＜0.05),차연합용약조적효과교임일단독용약조경위명현(t=11.33,9.37,P＜0.01).결론 황기통과촉진세포조망유효제고순박대Hep-2세포억제작용적민감성,통과조절Bcl-2/Bax단백표체,능제고순박대후암적치료효과.
Objective To study the anti-proliferation and apoptosis induction effect of cisplatin combined with Astragalus on human laryngeal cancer Hep-2 cells.Methods The proliferation inhibition of cisplatin and Astragalus alone or in combination on Laryngeal cancer Hep-2cells was measured by MTT assay.Effects of cisplatin and Astragalus alone or in combination on apoptosis of Hep-2 cells were detected by flow cytometry (FCM).Western blot was used to analyze the expressions of Bcl-2 and Bax proteins.Results The inhibition ratio of proliferation of Hep-2 cells was (53.83 ± 17.12) ％ in the astragalus group,(69.12 ± 27.12)％ in the cisplatin group,and (84.55 ± 27.84)％ in the cisplatin combined with Astragalus group,and was significantly greater than the control group (0％) (t =16.87,16.67,40.90,P ＜0.01),respectively.The apoptotic ratio of Hep-2 cells was (38.2 ± 13.6)％ in the astragalus group,(67.2 ± 17.8)％ in the cisplatin group,and (86.4 ± 25.1)％] in the cisplatin combined with Astragalus group,and was significantly greater than control group (17.1 ± 1.3) ％ (t =8.11,12.77,24.92,P ＜0.05),respectively.The effect in the combination group is better than the other group (t =11.33,9.37,P ＜ 0.01).The expressions of Bcl-2 and Bax proteins were changed.Conclusions The tumor-killing effect of cisplatin on laryngeal cancer Hep-2 cells could be enhanced significantly by the combination application of astragalus by the way of regulating the expression of Bcl-2/Bax.
